Approval · Notice of Compliance 20731 · 2018
XULTOPHY: Notice of Compliance 20731
Issued April 11, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20731
- Date
- April 11, 2018
- Company
- Novo Nordisk Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XULTOPHY | 02474875 | Cancelled Post Market |
Medicinal ingredients
- LIRAGLUTIDE 3.6 MG per ML
- INSULIN DEGLUDEC 100 UNIT per ML